Document:

EX-10.1

 Exhibit 10.1 

PPI HOLDINGS, INC. 

2018 STOCK INCENTIVE PLAN 

1. Purpose. 
 This PPI
Holdings, Inc. 2018 Stock Incentive Plan (hereinafter referred to as this “Plan”) is intended to promote the best interests of the Corporation and its stockholders by (i) enabling the Corporation and any Parent or Subsidiary to
attract and retain persons of ability as employees, directors, consultants and advisors, (ii) providing an incentive to such persons to contribute to the growth of the Corporation by affording such persons equity participation in the
Corporation and (iii) rewarding those employees, directors, consultants and advisers who contribute to the operating progress and earning power of the Corporation or any Parent or Subsidiary. 

2. Definitions. 
 The
following terms shall have the following meanings when used herein unless the context clearly requires otherwise: 
 A. “Board of
Directors” means the Board of Directors of the Corporation. 
 B. “Code” means the Internal Revenue Code of 1986,
as amended, or any successor statute. 
 C. “Common Stock” means the Common Stock of the Corporation, par value $0.0001 per
share. 
 D. “Controlling Participant” means any Eligible Person who, immediately before any Option is granted to that
particular Eligible Person, directly or indirectly possesses more than ten percent (10%) of the total combined voting power of all classes of stock of the Corporation (or any Parent or Subsidiary). 

E. “Committee” means any committee of the Board of Directors to which the Board of Directors delegates any responsibility for
the implementation, interpretation or administration of this Plan. 
 F. “Corporation Law” means the General Corporation Law
of the State of Delaware. 
 G. “Corporation” means PPI Holdings, Inc., a Delaware corporation. 

H. “Eligible Person” means any employee or director of, or consultant or adviser to, the Corporation or any Parent or
Subsidiary. 
 I. “Exercise Price” means the price at which a share of Incentive Stock may be purchased by a particular
Participant pursuant to the exercise of an Option. 
 J. “Fair Market Value” means the value of a share of Incentive Stock
as determined by the Board of Directors in a manner that the Board of Directors believes to be in accordance with the Code. 
 K.
“Incentive Stock” means shares of Common Stock issued pursuant to this Plan. 
 L. “ISO” means an Option
(or a portion thereof) intended to qualify as an “incentive stock option” within the meaning of Section 422 of the Code, or any successor provision. 

M. “NQSO” means an Option (or a portion thereof) which is not intended to, or does not, qualify for any reason as an
“incentive stock option” within the meaning of Section 422 of the Code, or any successor provision. 
 N.
“Option” means the right of a Participant to purchase shares of Incentive Stock in accordance with the terms of this Plan and a Stock Option Agreement between such Participant and the Corporation. 

O. “Parent” means any corporation (other than the Corporation) in an unbroken chain of corporations ending with the
Corporation if, at the time of granting of an Option, each of the corporations (other than the Corporation) owns stock possessing at least fifty percent (50%) of the total combined voting power of all classes of stock in one of the other
corporations in such chain. 

  
 1 

 P. “Participant” means any Eligible Person to whom an Option or Restricted Stock
has been granted pursuant to this Plan and who is a party to a Stock Option Agreement or Restricted Stock Agreement, as the case may be. 

Q. “Plan Year” means any calendar year during which this Plan is effective. 

R. “Restricted Stock” means shares of Common Stock issued to a Participant pursuant to this Plan which are subject to certain
restrictions as set forth in a Restricted Stock Agreement. 
 S. “Restricted Stock Agreement” means an agreement by and
between a Participant and the Corporation setting forth the specific terms and conditions of a Right as well as the specific terms and conditions under which Restricted Stock may be purchased by such Participant pursuant to the exercise of such
Right. Each Restricted Stock Agreement shall be subject to the provisions of this Plan (which shall be incorporated by reference therein), and shall contain such provisions as the Board of Directors of the Corporation, in its sole discretion, may
authorize. 
 T. “Right” means the right of a Participant to purchase shares of Restricted Stock in accordance with the
terms of this Plan and the Restricted Stock Agreement(s) to which such Participant and the Corporation are parties. 
 U.
“SAR” means the right of a Participant to receive cash or other consideration equal to the difference between the Fair Market Value of the Incentive Stock covered by all or any unexercised portion of an Option on the date of
exercise of the SAR and the Fair Market Value of such Incentive Stock on the date of grant of the SAR. 
 V. “Stock Option
Agreement” means an agreement by and between a Participant and the Corporation setting forth the specific terms and conditions of an Option and/or SAR, which shall establish the specific terms and conditions under which Incentive Stock may
be purchased by such Participant pursuant to the exercise of such Option. Each Stock Option Agreement shall be subject to the provisions of this Plan (which shall be incorporated by reference therein) and shall contain such provisions as the Board
of Directors, in its sole discretion, may authorize. 
 W. “Subsidiary” means any corporation (other than the Corporation)
in an unbroken chain of corporations beginning with the Corporation if, at the time of granting of an Option, each of the corporations (other than the last corporation in the unbroken chain) owns stock possessing at least fifty percent (50%) of the
total combined voting power of all classes of stock in one of the other corporations in such chain. 
 X. “Warrant” means
any right of a Participant to purchase shares of Incentive Stock in accordance with the terms of this Plan and a Warrant Agreement between such Participant and the Corporation which provides for vesting of such Right only upon the occurrence of a
certain event or events, and not by the mere passage of time following the grant of the Right. 
 Y. “Warrant Agreement”
means an agreement by and between a Participant and the Corporation setting forth the specific terms and conditions of any Warrant, which shall establish the specific terms and conditions under which Incentive Stock may be purchased by such
Participant pursuant to the exercise of such Warrant following vesting. Each Warrant Agreement shall be subject to the applicable provisions of this Plan (which shall be incorporated by reference therein) and shall contain such provisions as the
Board of Directors, in its sole discretion, may authorize. 
 3. Adoption and Administration of Plan. 

A. This Plan shall become effective upon its adoption by the Board of Directors; provided, however, that the stockholders of the
Corporation shall approve this Plan in accordance with the Corporation Law within twelve (12) months before or after the adoption of the Plan by the Board of Directors. In the event that the stockholders of the Corporation shall not approve
this Plan in accordance with the Corporation Law, within twelve (12) months after the adoption of this Plan by the Board of Directors, this Plan shall expire by its terms. No Option, SAR, grant of Restricted Stock or other award hereunder shall
be exercisable or payable in any respect prior to such approval of this Plan by the stockholders of the Corporation. 
 B. Any Option granted
pursuant to this Plan shall be granted within ten (10) years from the date that this Plan is adopted by the Board of Directors or the date that this Plan is approved by the stockholders of the Corporation, whichever is earlier. 

  
 2 

 C. The Board of Directors shall implement, interpret (except as expressly provided in this Plan)
and administer this Plan. Without limiting the powers and authority of the Board of Directors in any respect, the Board of Directors shall have authority: 

(i) to construe and interpret this Plan and any Stock Option Agreement or Restricted Stock Agreement entered into hereunder; 

(ii) to determine the Fair Market Value of Incentive Stock; 

(iii) to select Eligible Persons to whom Options or Restricted Stock may from time to time be granted hereunder; 

(iv) to determine whether any Option or any portion thereof shall be an ISO or a NQSO; 

(v) to determine the number of shares of Incentive Stock to be covered by any Option and the Exercise Price applicable to any Option; 

(vi) to determine the number of shares of Restricted Stock to be covered by any Restricted Stock Agreement; 

(vii) to determine the terms and conditions, not inconsistent with the terms of this Plan, of any Option and to approve forms of Stock Option
Agreements; 
 (viii) to determine the terms and conditions, not inconsistent with the terms of this Plan, of any grant of Restricted Stock
and to approve forms of Restricted Stock Agreements; 
 (ix) to determine the terms and conditions, not inconsistent with the terms of this
Plan, of any grant of Warrants and to approve forms of Warrant Agreements to determine whether, and under what circumstances, a Warrant may be settled or paid in cash or other consideration; 

(x) to amend, cancel, accept the surrender of, modify or accelerate the vesting of all or any portion of an Option, including amendments or
modifications that may cause an ISO to become a NQSO; 
 (xi) to amend, cancel, accept the surrender of, modify or terminate the
restrictions on a Right or Restricted Stock set forth in any Restricted Stock Agreement; 
 (xii) to amend, cancel, accept the surrender of,
modify or terminate the restrictions on a Warrant set forth in any Warrant Agreement 
 (xiii) to authorize and implement any amendment, as
required by the Code or with the consent of the Participant, to any Stock Option Agreement and the terms of any Option evidenced thereby, or to any Restricted Stock Agreement and the terms of any Right evidenced thereby; 

(xiv) to establish policies and procedures for the exercise of Options and the satisfaction of withholding or other obligations arising in
connection therewith; 
 (xv) to establish policies and procedures for the exercise of Rights and the purchase of Restricted Stock; 

(xvi) to establish policies and procedures for the exercise of Warrants and the satisfaction of withholding or other obligations arising in
connection therewith 
 Any action taken by the Board of Directors with respect to the implementation, interpretation or administration of
this Plan shall be final, conclusive and binding. 
 D. To the extent not prohibited by the Corporation Law or the charter or bylaws of the
Corporation, the Board of Directors may delegate any or all of its responsibilities hereunder to the Committee, and all references herein or in any Warrant Agreement, Stock Option Agreement or Restricted Stock Agreement to the “Board of
Directors” shall, to the extent applicable, be deemed to refer to and include the Committee. 

  
 3 

 4. Total Number of Shares of Incentive Stock and Restricted Stock. 

The number of shares of Incentive Stock and Restricted Stock which (i) may be issued by the Corporation under this Plan pursuant to the
exercise of Options granted hereunder, (ii) may be covered by SAR’s granted hereunder which have not expired unexercised, and (iii) may be issued by the Corporation under this Plan pursuant to the exercise of Rights granted hereunder,
shall not exceed an aggregate of five million (5,000,000) shares, which amount may be increased only by a resolution adopted by the Board of Directors and approved by the stockholders of the Corporation in accordance with the Corporation Law within
twelve (12) months after such adoption by the Board of Directors. Such shares of Incentive Stock and Restricted Stock may be issued out of the authorized and unissued or reacquired Common Stock of the Corporation. Any shares subject to an
Option, Warrant, SAR, Right or portion thereof which expires or is terminated unexercised (unless by virtue of the exercise of an Option, SAR or Right granted in tandem therewith) as to such shares may again be subject to an Option, Warrant, SAR or
Right under this Plan. To the extent there shall be any adjustment in the number of shares of Incentive Stock and/or Restricted Stock pursuant to the provisions of Section 9 hereof, the aforesaid aggregate number of shares which may be issued
by the Corporation under this Plan shall be likewise adjusted. 
 5. Grants and Awards. 

A. As soon as practicable after the Board of Directors determines to award an Option, Warrant, SAR or Right, the appropriate officer or
officers of the Corporation shall give notice (written or oral) to such effect to each Eligible Person designated to be awarded an Option, Warrant, SAR or Right, which notice shall be accompanied by a copy or copies of the Stock Option Agreement,
Warrant Agreement, or Restricted Stock Agreement (as applicable) to be executed by such Eligible Person. The Board of Directors may delegate to the appropriate officer or officers of the Corporation the authority to prepare, execute and deliver any
Stock Option Agreement, Warrant Agreement or Restricted Stock Agreement evidencing any Option, Warrant, SAR or Right granted under this Plan; provided, however, that any such Stock Option Agreement, Warrant, or Restricted Stock
Agreement shall be consistent with the terms and conditions of this Plan. 
 B. Notwithstanding the generality of Section 5.A hereof,
for any Plan Year no award of any Option, Warrant, SAR or Right to any Eligible Person who is a member of the Board of Directors and not otherwise an employee of the Corporation or any Parent or Subsidiary (a
“Non-Management Director”) shall exceed the right to acquire more than thirty thousand (30,000) shares of Common Stock. Subject to the approval of the Board of Directors, this Plan authorizes the
grant of Options, Warrants, SAR’s or Rights of up to thirty thousand (30,000) shares of Common Stock per Plan Year to any Non-Management Director. 

C. Upon receipt of the notice specified in Section 5.A hereof, an Eligible Person shall have an Option, Warrant, SAR or Right (as the case
may be). Such Eligible Person shall nonetheless become and be a Participant only after the due execution and delivery by such Eligible Person and the Corporation of a Stock Option Agreement, Warrant Agreement, or Restricted Stock Agreement (in such
form and number as the officer or officers of the Corporation shall direct) by such date and time as shall be specified in such notice (unless waived by the Corporation). 

D. For any Option intended to qualify as an ISO, in whole or in part, (i) the Eligible Person shall then be an employee of the Corporation
or a Parent or Subsidiary, as provided in the Code, (ii) the term during which such Option shall be in effect shall not be greater than ten (10) years, except in the case of an Option granted to a Controlling Participant, in which case the
term shall not be greater than five (5) years, (iii) the Exercise Price shall not be less than one hundred percent (100%) of the Fair Market Value on the date that such Option is granted, except in the case of an ISO granted to a Controlling
Participant, in which case the Exercise Price shall not be less than one hundred ten percent (110%) of the Fair Market Value on the date that such Option is granted and (iv) such Option shall be exercisable only by the Participant during his or
her lifetime and shall be nontransferable by the Participant unless the Stock Option Agreement permits such Option to be transferred by will or the laws of descent and distribution. 

E. The purchase price for each share of Restricted Stock, as determined by the Board of Directors, need not be the Fair Market Value thereof,
and may vary from one Participant to another. In addition, the terms and conditions on which shares of Restricted Stock may be purchased may vary from one Participant to another. In computing the purchase price of a share of Restricted Stock, the
Board of Directors may take into consideration, without limitation, the restrictions on transfer or other dispositions imposed in the applicable Restricted Stock Agreement. 

  
 4 

 F. In the event that the Corporation or any Parent or Subsidiary assumes an option granted by
another entity, which option is to be covered by this Plan and upon the exercise of which shares of Incentive Stock are to be issued, the terms and conditions of such option shall remain unchanged (except the exercise price and the number and nature
of shares issuable upon exercise thereof, which shall be adjusted appropriately in accordance with the Code, and references to such other entity, which shall be deemed to refer to the Corporation). In the event that the Board of Directors elects to
grant an Option, SAR or Right under this Plan to replace an option, SAR or right granted by another entity (rather than assume such option, SAR or Right), the holder of such option or SAR shall be eligible to receive such replacement Option, SAR or
Right, which may be granted with a similarly-adjusted Exercise Price. 
 6. Exercise and Termination of Options, Warrants, SAR’s and
Rights. 
 A. An Option or SAR of a Participant may be exercised during the period such Option or SAR is in effect and as set forth
herein and in the Stock Option Agreement, and only if compliance with all applicable federal and state securities laws can be effected. An Option or SAR may be exercised only by (i) the Participant’s completion, execution and delivery to
the Corporation of a notice of such Participant’s exercise of such Option and an “investment letter” (if required by the Corporation) as supplied by the Corporation and (ii) the payment to the Corporation of the aggregate
Exercise Price, in accordance with Section 6.C hereof and the Stock Option Agreement, for the shares of Incentive Stock to be purchased pursuant to such exercise (as shall be specified by such Participant in such notice). Except as otherwise
specifically provided by a duly executed Stock Option Agreement or unless waived by the Board of Directors, an Option or any of the rights thereunder may be exercised by such Participant only, and may not be transferred or assigned, voluntarily,
involuntarily or by operation of law (including, without limitation, the laws of bankruptcy, intestacy, descent and distribution and succession). 

B. A Warrant may be exercised upon or following the occurrence of the certain event effecting vesting of the Warrant as set forth in the
applicable Warrant Agreement or, as applicable, the Plan, and then only if compliance with all applicable federal and state securities laws can be effected. A Warrant may be exercised only by (i) the Participant’s completion, execution and
delivery to the Corporation of a notice of such Participant’s exercise of such Warrant and an “investment letter” (if required by the Corporation) as supplied by the Corporation and (ii) the payment to the Corporation of the
aggregate Exercise Price, in accordance with Section 6.D hereof and the Warrant Agreement, for the shares of Incentive Stock to be purchased pursuant to such exercise (as shall be specified by such Participant in such notice). Except as
otherwise specifically provided by a duly executed Warrant Agreement or unless waived by the Board of Directors, a Warrant or any of the rights thereunder may be exercised by such Participant only, and may not be transferred or assigned,
voluntarily, involuntarily or by operation of law (including, without limitation, the laws of bankruptcy, intestacy, descent and distribution and succession). 

C. A Right of a Participant may be exercised during the period such Right is in effect and as set forth herein and in the Restricted Stock
Agreement, and only if compliance with all applicable federal and state securities laws can be effected. A Right may be exercised only by (i) the Participant’s completion, execution and delivery to the Corporation of a notice of such
Participant’s exercise of such Right (if such exercise is not simultaneous with the execution of the applicable Restricted Stock Agreement) and an “investment letter” (if required by the Corporation) as supplied by the Corporation and
(ii) the payment to the Corporation of the aggregate Exercise Price, in accordance with Section 6.C hereof and the Restricted Stock Agreement, for the shares of Restricted Stock to be purchased pursuant to such exercise (as shall be
specified by such Participant in such notice). Except as otherwise specifically provided by a duly executed Restricted Stock Agreement or unless waived by the Board of Directors, a Right or any of the rights thereunder may be exercised by such
Participant only, and may not be transferred or assigned, voluntarily, involuntarily or by operation of law (including, without limitation, the laws of bankruptcy, intestacy, descent and distribution and succession). 

D. Payment by each Participant for the shares of Incentive Stock or Restricted Stock purchased hereunder upon the exercise of an Option,
Warrant, or a Right shall be made (i) in cash, (ii) by good check payable to the Corporation or electronic funds transfer of immediately available funds to the Corporation, or (iii) in accordance with the terms of the applicable Stock
Option Agreement, Warrant Agreement, or Restricted Stock Agreement executed by such Participant. 

  
 5 

 E. The Board of Directors at any time or from time to time may offer to buy out for a payment in
cash or Incentive Stock all or a portion of an outstanding Option or Warrant held by a Participant, based on such terms and conditions as the Board of Directors shall establish and communicate to the Participant at the time that such offer is made.
The Board of Directors may provide for the surrender of all or any portion of an Option or Warrant in satisfaction of specified obligations of a Participant, including tax withholding obligations. 

F. In the event that the Corporation shall complete any transaction or series of transactions resulting in the reorganization of the
Corporation where the stockholders of the Corporation immediately prior to the closing of such transaction or series of transaction retain voting control of the Corporation either directly or through control of any successor, parent, or affiliate of
the Corporation (each, a “Successor”), then the Board of Directors may, in its sole and absolute discretion, elect to exchange any Option, Warrant, or SAR granted to any Participant prior to such closing for an equivalent Option, Warrant,
or SAR in the Successor or the same terms and conditions and Exercise Price as the award or grant under this Plan. 
 G. As a condition to
the exercise of any Option, Warrant, or SAR (for non-cash consideration), the Corporation shall have the right to require that the Participant (or the recipient of any shares of Incentive Stock or noncash
consideration) remit to the Corporation or any Parent or Subsidiary an amount calculated by the Corporation to be sufficient to satisfy applicable federal, state, foreign or local withholding tax requirements prior to the delivery of any stock
certificate evidencing shares of Incentive Stock or other form of non-cash consideration; in lieu thereof, the Participant may satisfy applicable withholding tax requirements by electing to have the
Corporation withhold from the Incentive Stock issuable upon exercise of an Option a number of whole shares having a Fair Market Value (determined on the date that the amount of tax to be withheld is to be fixed) at least equal to the aggregate
amount required to be withheld. Whenever any payments are to be made in cash (upon the exercise of a SAR or otherwise), the Corporation shall be entitled, in its sole discretion, to deduct from such payment such amount calculated by the Corporation
to be sufficient to satisfy applicable federal, state, foreign or local withholding tax requirements thereon. 
 7. Costs and
Expenses. 
 All costs and expenses with respect to the adoption, implementation, interpretation and administration of this Plan shall be
borne by the Corporation; provided, however, that, except as otherwise specifically provided in this Plan or the applicable Stock Option Agreement, Warrant Agreement, or Restricted Stock Agreement between the Corporation and a
Participant, the Corporation shall not be obligated to pay any costs or expenses (including legal fees) incurred by any Participant in connection with any Stock Option Agreement, Warrant Agreement, Restricted Stock Agreement, this Plan or any
Option, Warrant, SAR, Right, Restricted Stock or Incentive Stock held by any Participant. 
 8. No Prior Right of Award. 

Nothing in this Plan shall be deemed to give any director, officer or employee of, or advisor or consultant to, the Corporation or any Parent
or Subsidiary, or such person’s legal representatives or assigns, or any other person or entity claiming under or through such person, any contract or other right to participate in the benefits of this Plan. Nothing in this Plan shall be
construed as constituting a commitment, guarantee, agreement or understanding of any kind or nature that the Corporation or any Parent or Subsidiary shall continue to employ, retain or engage any person (whether or not a Participant). This Plan
shall not affect in any way the right of the Corporation and any Parent or Subsidiary to terminate the employment or engagement of any person (whether or not a Participant) at any time and for any reason whatsoever and to remove any person (whether
or not a Participant) from any position as a director or officer. No change of a Participant’s duties as an employee of the Corporation or any Parent or Subsidiary shall result in a modification of the terms of any rights of such Participant
under this Plan or any Stock Option Agreement, Warrant Agreement, or Restricted Stock Agreement executed by such Participant. 
 9.
Changes in Capital Structure. 
 Subject to any required action by the stockholders of the Corporation and the provisions of the
Corporation Law, the number of shares of: 
 (i) Incentive Stock represented by the unexercised portion of an Option, Warrant, or SAR; 

(ii) Restricted Stock represented by the unexercised portion of a Right; and 

  
 6 

 (iii) Incentive Stock and Restricted Stock which have been authorized or reserved for issuance
hereunder (whether such shares are unissued, reacquired or subject to an Option, Warrant, SAR or Right that expired, was cancelled, surrendered or terminated unexercised as to such shares), as well as the Exercise Price under the unexercised portion
of an Option, Warrant or SAR and the purchase price of a share of Restricted Stock represented by the unexercised portion of a Right, shall be proportionately adjusted for (a) each division, combination or reclassification of any of the shares
of Common Stock of the Corporation and (b) each dividend declared by the Board of Directors and payable in shares of Common Stock of the Corporation. 

10. Amendment or Termination of Plan. 

Except as otherwise provided herein or as required by law, this Plan may be amended or terminated in whole or in part by the Board of Directors
(in its sole discretion), but no such action shall adversely affect or alter any right or obligation with respect to any Option, Warrant, SAR, Right, Stock Option Agreement or Restricted Stock Agreement then in effect, except to the extent that any
such action shall be required or desirable (in the opinion of the Corporation or its counsel) so that any Option intended to qualify as an ISO complies with the Code or any rule or regulation promulgated or proposed thereunder. 

11. Burden and Benefit. 

The terms and provisions of this Plan shall be binding upon, and shall inure to the benefit of, each Participant and such Participant’s
executors and administrators, estate, heirs and personal and legal representatives. 
 12. Headings. 

The headings and other captions contained in this Plan are for convenience of reference only and shall not be used in interpreting, construing
or enforcing any of the provisions of this Plan. 
 13. Interpretation. 

Notwithstanding any provision of this Plan or any provision of any Stock Option Agreement evidencing an Option that is intended, in whole or in
part, to qualify as an ISO, this Plan and each such Stock Option Agreement are intended to comply with all requirements for qualification under the Code and with any rule or regulation promulgated or proposed thereunder, and shall be interpreted and
construed in a manner which is consistent with this Plan and each such Stock Option Agreement being so qualified. 
 14. Governing
Law. 
 This Plan shall be governed by, and construed in accordance with, the substantive laws of the Corporation’s jurisdiction of
incorporation (other than provisions thereof relating to conflicts of law and choice of law). 

  
 7 

 PPI 2018 SIP AGT-I 

STOCK OPTION AGREEMENT 

Unless otherwise defined herein, the terms defined in the PPI Holdings, Inc. 2018 Stock Incentive Plan (the “Plan”) shall have the
same defined meanings in this Stock Option Agreement (the “Option Agreement”). 
  

	 	A.	 NOTICE OF STOCK OPTION GRANT 

Name: 
 The undersigned
Participant has been granted an Option to purchase shares of Common Stock (“Shares”) of the Corporation, subject to the terms and conditions of the Plan and this Option Agreement, as follows: 

 

			
	Grant Date:	  	
	Vesting Commencement Date:	  	
	Exercise Price per Share:	  	$
	Total Number of Shares Granted:	  	
	Type of Option:	  	☐ ISO
		  	☐ NQSO
	Term/Expiration Date:	  	10th anniversary of Grant Date

 Vesting Schedule: 

Subject to the accelerated vesting provisions below, this Option shall be exercisable, in whole or in part, according to the following vesting
schedule: 
 Fifty percent (50%) of the Shares subject to the Option shall vest on the Grant Date and twenty-five percent (25%) of the Shares
subject to the Option shall vest on each yearly anniversary of the Grant Date, subject to Participant continuing to be an Eligible Person through each such date, such that the Option shall be fully vested as of the second anniversary of the Grant
Date. 
 Accelerated Vesting: 

Notwithstanding the Vesting Schedule above, upon a Change in Control (as defined below), the number of Shares scheduled to vest as of the next
occurring vesting date shall immediately vest as if such vesting date has occurred as of the occurrence of the Change of Control subject to Participant continuing to be an Eligible Person through such date. 

Termination Period: 
 This
Option shall be exercisable for thirty (30) days after Participant ceases to be an Eligible Person, unless such termination is due to Participant’s death or disability, in which case this Option shall be exercisable for twelve
(12) months after Participant ceases to be an Eligible Person. Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided above and this Option may be subject to earlier
termination as provided in Section 11 of the Agreement. 
 Notice Requirement: 

Participant must provide the Corporation advanced written notice of no less than forty (40) business day prior to voluntarily terminating
status as an Eligible Person (the “Notice Requirement”). Notwithstanding anything herein to the contrary, if Participant does not comply with the Notice Requirement, then all Shares subject to the Option (whether vested or unvested) shall
immediately terminate without consideration and/or any post-termination exercise period. 
 Restrictive Covenants: Without limiting
any confidentiality, invention assignment agreement or other similar agreements between Participant and the Corporation, Participant hereby agrees to the following covenants set forth below (collectively, the “Restrictive Covenants”).
Notwithstanding anything herein to the contrary, if Participant 

  
 8 

 
violates any of the Restrictive Covenants, then all Shares subject to the Option (whether vested or unvested) shall immediately terminate without consideration and/or any post-termination
exercise period. Participant acknowledges and agrees that the Restrictive Covenants shall apply following the purchase of Shares subject to the Option as set forth in Section 6 of the Exercise Notice, which is incorporated herein by reference.
For all purposes of the Plan and this Option Agreement, the administrator of the Plan (the “Administrator”) shall have the right to determine if there has been a violation of the Restrictive Covenants in its sole reasonable good-faith
discretion. The Restrictive Covenants are as follows: 
 Non-Disclosure: Participant will
hold in the strictest confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of Confidential Information (as defined below), and Participant will not (i) use the Confidential Information for any purpose
whatsoever other than as necessary for the performance of services on behalf of the Corporation, or (ii) disclose the Confidential Information to any third party without the prior written consent of an authorized representative of Corporation.
Participant may disclose Confidential Information to the extent compelled by applicable law; provided however, prior to such disclosure, Participant shall provide prior written notice to Corporation and seek a protective order or such similar
confidential protection as may be available under applicable law. Participant agrees that no ownership of Confidential Information is conveyed to the Participant. Without limiting the foregoing, Participant shall not use or disclose any Corporation
property, intellectual property rights, trade secrets or other proprietary know-how of the Corporation to invent, author, make, develop, design, or otherwise enable others to invent, author, make, develop, or
design identical or substantially similar designs as those developed under his or her service relationship with the Corporation for any third party. 

Non-Solicitation: For twenty-four (24) months following a Participant’s termination
of status as an Eligible Person, Participant agrees not to personally solicit any of the employees either of the Corporation or any Parent or Subsidiary to become employed elsewhere or provide the names of such employees to any other company that
Participant has reason to believe will solicit such employees. 
 Non-Compete: For
twenty-four (24) months following a Participant’s termination of status as an Eligible Person, Participant shall not, whether as an employee, officer, director, independent contractor, consultant, agent or otherwise, (a) provide
services directly or indirectly to any party other than the Corporation or the applicable Parent or Subsidiary within the Restricted Business, or (b) encourage, solicit, induce, or otherwise facilitate any party to materially reduce or
terminate its use of any of the products or services provided by the Corporation or any Parent or Subsidiary. 
 Invention Clause: To
the extent that, in the course of performing the services to the Corporation, Participant jointly or solely conceives, develops, or reduces to practice any inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, based on Confidential Information obtained from the Corporation and pertaining to the
Corporation’s business, Participant hereby agrees to assign all rights, titles and interest to such inventions to the Corporation. 

Definitions. The following terms shall have the following meanings when used in the Option Agreement: 

“Change in Control” means a change in the ownership of the Corporation which occurs on the date that any one person, or more
than one person acting as a group (“Person”), acquires, in a single transaction or a series of related transactions, either (a) all or substantially all of the assets of the Corporation (or the Parent of the Corporation); or
(b) ownership of the stock of the Corporation that, together with the stock held by such Person, which constitutes more than fifty percent (50%) of the total voting power of the stock of the Corporation, except that any change in the ownership
of the stock of the Corporation as a result of a private placement of the securities of the Corporation that is approved by the Board of Directors will not be considered a Change in Control unless the Board affirmatively determines that such private
placement shall be considered a Change in Control hereunder. 
 “Confidential Information” means any non-public information that relates to the actual or anticipated business and/or products, research or development of the Corporation, its affiliates or subsidiaries, or to the Corporation’s, its
affiliates’ or subsidiaries’ technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the Corporation’s, its
affiliates’ or subsidiaries’ products or services and markets therefor, customer lists and customers (including, but not limited to, customers of the Corporation on whom Participant called or with whom Participant became acquainted during
the term of Participant’s service relationship with the 

  
 9 

 
Corporation), software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business
information disclosed by the Corporation, its affiliates or subsidiaries, either directly or indirectly, in writing, orally or by drawings or inspection of premises, parts, equipment, or other property of Corporation, its affiliates or Subsidiaries.
Notwithstanding the foregoing, Confidential Information shall not include any such information which Participant can establish (i) was publicly known or made generally available prior to the time of disclosure to Participant; (ii) becomes
publicly known or made generally available after disclosure to Participant through no wrongful action or inaction of Participant; or (iii) is in the rightful possession of Participant, without confidentiality obligations, at the time of
disclosure as shown by Participant’s then-contemporaneous written records. 
 “Restricted Business” means the
provision of products or services which provide for or otherwise enable the treatment or diagnosis of cancer using any technology, rights, or patents owned or licensed by the Corporation. 

“Successor” shall have the meaning set forth in Section 6.F of the Plan. 

 

	 	B.	 AGREEMENT 

1. Grant of Option. (a) The administrator of the Plan (the “Administrator”) hereby grants to the Participant named in the
Notice of Stock Option Grant in Part A of this Agreement (“Participant”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the
Notice of Stock Option Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to Section 10 of the Plan, in the event of a conflict between the terms and
conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail. 
 (b) If designated in the Notice of
Stock Option Grant as an ISO, this Option is intended to qualify as an “incentive stock option” as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this
Option shall be treated as a NQSO. Further, if for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NQSO granted under the
Plan. In no event shall the Administrator, the Corporation or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any
reason as an ISO. 
 2. Exercise of Option. 

(a) Right to Exercise. This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of
Stock Option Grant and with the applicable provisions of the Plan and this Option Agreement. 
 (b) Method of Exercise. This Option
shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to
exercise the Option, the number of Shares with respect to which the Option is being exercised (the “Exercised Shares”), and such other representations and agreements as may be required by the Corporation. The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as provided in this Option Agreement as to all Exercised Shares, together with any applicable tax withholding. This Option shall be deemed to be exercised upon receipt by the Corporation of such
fully executed Exercise Notice accompanied by the aggregate Exercise Price, together with any applicable tax withholding. 
 (c)
Compliance Required. No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise comply with applicable laws. Assuming such compliance, for income tax purposes the Shares shall be considered
transferred to Participant on the date on which the Option is exercised with respect to such Shares. 
 3. Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), at the time this Option is exercised, Participant shall, if required by the Corporation,
concurrently with the exercise of all or any portion of this Option, deliver to the Corporation his or her Investment Representation Statement in the form attached hereto as Exhibit B. 

  
 10 

 4. Lock-Up Period. (a) Participant hereby
agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of,
directly or indirectly, any Common Stock (or other securities) of the Corporation or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock
(or other securities) of the Corporation held by Participant (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Corporation not to exceed one
hundred and eighty (180) days following the effective date of any registration statement of the Corporation filed under the Securities Act (or such other period as may be requested by the Corporation or the underwriters to accommodate
regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule
472(f)(4), or any successor provisions or amendments thereto). 
 (b) Participant agrees to execute and deliver such other agreements as may
be reasonably requested by the Corporation or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Corporation or the representative of the underwriters of
Common Stock (or other securities) of the Corporation, Participant shall provide, within ten (10) days of such request, such information as may be required by the Corporation or such representative in connection with the completion of any
public offering of the Corporation’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall not apply to a registration relating solely to employee benefit plans on
Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Corporation may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of said one hundred and eighty (180) day (or other) period. Participant agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 4. 

5. Method of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the
election of the Participant: 
 (a) cash; or 

(b) a good check payable to the Corporation or an electronic funds transfer of immediately available funds to an account of the Corporations
specified in writing to Participant; or 
 (c) only in the event of a Change in Control, net exercise such that the Participant shall
receive, without payment as prescribed in Section 5(a) or Section 5(b) of the Exercise Price, such that the Participant shall receive a number of shares of Common Stock equal to (i) the product of (x) the gross number of Exercise
Shares specified in the applicable Exercise Notice multiplied by (y) the per share Fair Market Value of the Common Stock as of the date of the applicable Change in Control, defined as the price per share payable for Common Stock pursuant to the
applicable terms and conditions of the Change in Control, or if the per share value paid for the assets of the Corporation (or Parent) pursuant to the Change in Control calculated on a fully-diluted,
as-converted basis; less (ii) the product of (x) the Exercise Price multiplied by (y) the number of Exercise Shares specified in the Exercise Notice ((i) less: (ii), the “Issued
Shares”); or 
 (d) at any time, surrender of other Shares which (i) shall be valued at its Fair Market Value on the date of
exercise, and (ii) must be owned free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator, shall not result in any adverse accounting consequences to the
Corporation. 
 6. Restrictions on Exercise. This Option may not be exercised until such time as the Plan has been approved by the
stockholders of the Corporation, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable law. 

  
 11 

 7. Non-Transferability of Option. 

(a) This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised
during the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant. 

(b) Further, until the Corporation becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or after the Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End Date”), Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than
(i) to persons who are “family members” (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of
Participant. Until the Reliance End Date, the Options and, prior to exercise, the Shares subject to this Option, may not be pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any “put
equivalent position” or any “call equivalent position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as
permitted in clauses (i) and (ii) of this paragraph. 
 8. Term of Option. This Option may be exercised only within the term set
out in the Notice of Stock Option Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option Agreement. 

9. Tax Obligations. 
 (a)
Tax Withholding. Participant agrees to make appropriate arrangements with the Corporation (or the Parent or Subsidiary employing or retaining Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax
withholding requirements applicable to the Option exercise. Participant acknowledges and agrees that the Corporation may refuse to honor the exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of
exercise. 
 (b) Notice of Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if
Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Date of Grant, or (ii) the date one (1) year after the date of exercise,
Participant shall immediately notify the Corporation in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Corporation on the compensation income recognized by Participant. 

(c) Code Section 409A. Under Code Section 409A, an Option that vests after December 31, 2004 (or that
vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the “IRS”) to be less than the Fair Market
Value of a Share on the date of grant (a “discount option”) may be considered “deferred compensation.” An Option that is a “discount option” may result in (i) income recognition by Participant prior to the exercise
of the Option, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result in additional state income, penalty and interest tax to the
Participant. Participant acknowledges that the Corporation cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share on the date of grant in a later
examination. Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible for
Participant’s costs related to such a determination. 
 10. Entire Agreement; Governing Law. The Plan is incorporated herein by
reference. The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Corporation and Participant with
respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Corporation and Participant. This Option Agreement is governed by the internal substantive laws but
not the choice of law rules of Delaware. 

  
 12 

 11. Change in Control. In the event of a Change in Control, the Option shall be assumed or
an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option (or portion thereof), the
Participant shall fully vest in and have the right to exercise the Option (or portion thereof) that is not assumed or substituted for as to all of the Shares subject to the Option, including Shares as to which it would not otherwise be vested or
exercisable. If an Option is not assumed or substituted for in the Change in Control, the Administrator shall notify the Participant in writing or electronically that the Option shall be fully exercisable for a period of limited period of time
following date of such notice, and the Option shall terminate upon the expiration of such period. For the purposes of this paragraph, the Option shall be considered assumed if, following the Change in Control, the option or right confers the right
to purchase or receive, for each Share subject to the Option immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in the Change in Control by holders of Common Stock for each
Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration
received in the Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of the
Option, for each Share subject to the Option, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Change in Control. 

12. Replacement by Successor. In the event that the Corporation shall complete any transaction or series of transactions resulting in
the reorganization of the Corporation where the stockholders of the Corporation immediately prior to the closing of such transaction or series of transaction retain voting control of the Corporation either directly or indirectly through a Successor
(a “Reorganization”), then, upon notice from the Administrator, this Option Agreement shall be terminated, surrendered, and null, void and of no further force or effect provided that the Successor forthwith following such notice deliver to
Participant another option agreement for the purchase of equity securities equivalent in value to the number of shares of the Corporation subject to this Option Agreement on the same terms and conditions and at the same Exercise Price as provided
for otherwise under this Option Agreement (a “replacement Award”), Participant agrees to surrender this Option Agreement upon demand by the Administrator as a mandatory condition to receive any Replacement Award. Notwithstanding such
notice, delivery of any Replacement Award, or surrender of this Option Agreement, upon closing of any Reorganization, this Option Agreement shall be converted solely into the right to receive a Replacement Award as provided for under this
Section 12 and Section 5.E of the Plan. 
 13. No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT
THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS AN ELIGIBLE PERSON AT THE WILL OF THE CORPORATION (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED,
BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED
PROMISE OF CONTINUED ENGAGEMENT AS AN ELIGIBLE PERSON FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE CORPORATION (OR THE PARENT OR SUBSIDIARY EMPLOYING OR
RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS AN ELIGIBLE PERSON AT ANY TIME, WITH OR WITHOUT CAUSE. 
 Participant
acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Participant agrees that the certain Stock
Option Agreement Participant originally entered into with Panacea Pharmaceuticals, Inc., a Maryland corporation (“Panacea”), dated [DATE] (the “Original Option Agreement”), is hereby surrendered and terminated. Concurrent with
such surrender of the Original Option Agreement and in accordance with Section 2.4 of that certain Agreement and Plan of Merger by and among the Company, Panacea, and PPI Acquisition I Corp. dated December 21, 2017 (the “Merger
Agreement”), the Original Option Agreement was converted solely into the right to receive this Option Agreement such that Participant shall have the right to purchase the same number of shares of Company Common Stock on the same terms and
conditions, subject to the same vesting schedule, and at the same price per share, as those shares of common stock of Panacea as set forth in the Original Option Agreement. 

  
 13 

 Participant agrees that this Option Agreement satisfies the obligations of the Company under
Section 2.4 of the Merger Agreement, that this Option Agreement replaces in its entirety the Original Option Agreement, and that the Original Option Agreement is null, void, and of no further force or effect. Participant has reviewed the Plan
and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Participant hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. Participant further agrees to notify the Corporation upon any change in the Notice of Stock Option Grant. 

 

					
	PARTICIPANT	 		  	PPI HOLDINGS, INC.
			
	  
	 		  	  

	Signature	 	                    	  	Signature
			
	  
	 		  	  

	Print Name	 		  	Print Name
			
	  
	 		  	  

	  
	 		  	Title
	Residence Address	 		  	

  
 14 

 EXHIBIT A 

PPI HOLDINGS, INC. STOCK INCENTIVE PLAN 

EXERCISE NOTICE 
 PPI Holdings, Inc. 

620 Professional Drive 

Gaithersburg, Maryland 20874 

Attention: Stock Plan Administrator 

1. Exercise of Option. Effective as of today,         ,     , the
undersigned (“Participant”) hereby elects to exercise Participant’s option (the “Option”) to purchase         shares of the Common Stock (the “Shares”) of PPI Holdings, Inc.
(the “Corporation”) under and pursuant to the PPI Holdings, Inc. Stock Incentive Plan (the “Plan”) and the Stock Option Agreement dated         , (the “Option Agreement”). 

2. Delivery of Payment. Participant herewith delivers to the Corporation the full purchase price of the Shares, as set forth in the
Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option. 
 3. Representations of
Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

4. Rights as Stockholder; Stockholders Agreement. Until the issuance of the Shares (as evidenced by the appropriate entry on the books
of the Corporation or of a duly authorized transfer agent of the Corporation), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to an Award, notwithstanding the exercise
of the Option. The Shares shall be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or other right for which the record date is prior to
the date of issuance except as provided in Section 9 of the Plan. Issuance of the Shares upon exercise of the Option shall require Participant to become a party to the certain Stockholders Agreement of the Corporation and Participant agrees to
execute the same promptly following delivery of this Exercise Notice 
 5. Corporation’s Repurchase Right. For a period of one
hundred eighty (180) days following the later of (i) issuance of any Shares from exercise of the Option (other than following a Change in Control), or (ii) if following issuance of such Shares, Participant shall cease to be an
Eligible Person, the Corporation shall have the unilateral right, but not the obligation, to repurchase such Shares from the Participant in consideration of a lump-sum payment equal to the aggregate Exercise
Price paid by the Participant in the form of cash, a good check payable to Participant, or electronic funds transfer of immediately available funds to a bank account specified by Participant (the “Repurchase Right”). The Purchase Right
shall be exercised by written notice (which may be delivered electronically to Participant) whereupon the Corporation shall pay amount due for such Shares in accordance with this Section 5 within five (5) days after the date of such
notice. Upon the making of such notice and provision of such payment, the applicable Shares shall be deemed repurchased by the Corporation and no further act of Participant shall be required to effect the transfer of such Shares from Participant to
the Corporation, and the Corporation shall be deemed the irrevocable attorney-in-fact of Participant to effect the transfer of such Shares pursuant to this
Section 5. 
 6. Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes
referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Corporation or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and
conditions set forth in this Section 6 (the “Right of First Refusal”) in addition to any rights of the Corporation or its stockholders as provide din the Stockholders Agreement. 

(a) Notice of Proposed Transfer. The Holder of the Shares shall deliver to the Corporation a written notice (the “Notice”)
stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to
each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the
Corporation or its assignee(s). 

  
 15 

 (b) Exercise of Right of First Refusal. At any time within thirty (30) days after
receipt of the Notice, the Corporation and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the
purchase price determined in accordance with subsection (c) below. 
 (c) Purchase Price. The purchase price (“Purchase
Price”) for the Shares purchased by the Corporation or its assignee(s) under this Section 5 shall be the Offered Price unless the Notice is provided within the one hundred eighty (180) day time periods described in Section 5 of
this Exercise Notice or if as of the date of the Notice the Holder is an Eligible Person, in which case the Purchase Price shall be the Exercise Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Corporation in good faith, subject to determination of the Purchase Price otherwise in accordance with this Section 6(c). 

(d) Payment. Payment of the Purchase Price shall be made, at the option of the Corporation or its assignee(s), in cash (by check), by
cancellation of all or a portion of any outstanding indebtedness of the Holder to the Corporation (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice
or in the manner and at the times set forth in the Notice. 
 (e) Holder’s Right to Transfer. If all of the Shares proposed in
the Notice to be transferred to a given Proposed Transferee are not purchased by the Corporation and/or its assignee(s) as provided in this Section 5, then subject to the applicable provisions of the Stockholders Agreement and applicable
securities laws, the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated within one hundred and twenty
(120) days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section 5 shall
continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice shall be given to the Corporation, and the Corporation
and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 

(f) Exception for Certain Family Transfers. Anything to the contrary contained in this Section 6 notwithstanding, the transfer of
any or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt
from the provisions of this Section 6. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the
Shares so transferred subject to the provisions of this Section 6, subject to the Stockholders Agreement, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 6 and the applicable
provisions of the Stockholders Agreement. 
 (g) Termination of Right of First Refusal. The Right of First Refusal shall terminate as
to any Shares upon the earlier of (i) the first sale of Common Stock of the Corporation to pursuant to a registration of such securities on Form S-1 or equivalent in accordance with the Securities Act of
1933, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. 
 7.
Restrictive Covenants. Participant reaffirms the terms of the Restrictive Covenants set forth in the Notice of Stock Option Grant. If Participant violates any of the Restrictive Covenants, the Corporation shall have the right for one hundred
eighty (180) days from such date a violation is determined by the Administrator (the “Determination Date”) to purchase from Participant, or Purchaser’s personal representative, as the case may be, all of the Participant’s
Shares received pursuant to exercise of the Option as of the date of such termination at the price paid by the Participant for such Shares (the “Repurchase Option”). For all purposes of the Plan, this Option Agreement and Exercise Notice,
the Administrator shall have the right to determine if there has been a violation of the Restrictive Covenants in its sole reasonable good-faith discretion. 

8. Notice Requirement. Participant reaffirms the terms of the Notice Requirement set forth in the Notice of Stock Option Grant. If
Participant violates the Notice Requirement, the Corporation shall have the right for one hundred eighty (180) days from such date a violation is determined by the Administrator (the “Determination Date”)

  
 16 

 
to purchase from Participant, or Purchaser’s personal representative, as the case may be, all of the Participant’s Shares exercised pursuant to the Option as of the date of such
termination at the price paid by the Participant for such Shares (the “Repurchase Option”). For all purposes of the Plan, this Option Agreement and Exercise Notice, the Administrator shall have the right to determine if there has been a
violation of the Notice Requirement in its sole reasonable good-faith discretion. 
 10. Tax Consultation. Participant understands
that Participant may suffer adverse tax consequences as a result of Participant’s purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection
with the purchase or disposition of the Shares and that Participant is not relying on the Corporation for any tax advice. 
 11.
Restrictive Legends and Stop-Transfer Orders. 
 (a) Legends. Participant understands and agrees that the Corporation shall
cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Corporation or by state or federal
securities laws: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY
NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS
IN COMPLIANCE THEREWITH. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, REPURCHASE RIGHTS,
AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER
RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE CORPORATION’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT
BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE CORPORATION OR THE MANAGING UNDERWRITER. 

(b) Stop-Transfer Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the
Corporation may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Corporation transfers its own securities, it may make appropriate notations to the same effect in its own records. 

(c) Refusal to Transfer. The Corporation shall not be required (i) to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have
been so transferred. 
 12. Successors and Assigns. The Corporation may assign any of its rights under this Exercise Notice to single
or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Corporation. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon Participant and his or
her heirs, executors, administrators, successors and assigns. 
 13. Interpretation. Any dispute regarding the interpretation of this
Exercise Notice shall be submitted by Participant or by the Corporation forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be final and binding on
all parties. 

  
 17 

 14. Governing Law; Severability. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the State of Delaware. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue
in full force and effect. 
 15. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise
Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Corporation and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Corporation and Participant. 

 

					
	Submitted by:	  		  	Accepted by:
			
	PARTICIPANT	  		  	PPI HOLDINGS, INC.
			
	  
	  	                    	  	  

	Signature	  		  	By
			
	  
	  		  	  

	Print Name	  		  	Print Name
		  		  	  

		  		  	Title
	Address:	  		  	Address:
	  
	  		  	  

	  
	  		  	  

		  		  	  

		  		  	Date Received

  
 18 

 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	PARTICIPANT	  	:	  	
			
	CORPORATION	  	:	  	PPI HOLDINGS, INC.
			
	SECURITY	  	:	  	COMMON STOCK
			
	AMOUNT	  	:	  	
			
	DATE	  	:	  	

 In connection with the purchase of the above-listed Securities, the undersigned Participant represents to the
Corporation the following: 
 (a) Participant is aware of the Corporation’s business affairs and financial condition and has acquired
sufficient information about the Corporation to reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s own account only and not with a view to, or for
resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

(b) Participant acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have
not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant’s investment intent as expressed herein. In this connection,
Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s representation was predicated solely upon a present intention to hold these
Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one (1) year or any other fixed period in the
future. Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges and
understands that the Corporation is under no obligation to register the Securities. Participant understands that the certificate evidencing the Securities shall be imprinted with any legend required under applicable state securities laws. 

(c) Participant is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance,
permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain conditions. Rule 701
provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under the Securities Act. In the event the Corporation becomes subject to the reporting
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt
under Rule 701 may be resold, subject to the satisfaction of the applicable conditions specified by Rule 144, including in the case of affiliates (1) the availability of certain public information about the Corporation, (2) the amount of
Securities being sold during any three (3) month period not exceeding specified limitations, (3) the resale being made in an unsolicited “broker’s transaction”, transactions directly with a “market maker” or
“riskless principal transactions” (as those terms are defined under the Securities Exchange Act of 1934) and (4) the timely filing of a Form 144, if applicable. 

(d) In the event that the Corporation does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in
certain limited circumstances subject to the provisions of Rule 144, which may require (i) the availability of current public information about the Corporation; (ii) the resale to occur more than a specified period after the purchase and
full payment (within the meaning of Rule 144) for the Securities; and (iii) in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth in sections (2), (3) and (4) of the paragraph immediately
above. 
 (e) Participant further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied,
registration under the Securities Act, compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of

  
 19 

 
the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to
Rules 144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at
their own risk. Participant understands that no assurances can be given that any such other registration exemption shall be available in such event. 
  

	
	PARTICIPANT
	
	  

	Signature
	
	  

	Print Name
	
	  

	Date

  
 20EX-10.3

 Exhibit 10.3 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE
COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 NON-EXCLUSIVE LICENSE AGREEMENT

 THIS NON-EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and effective
as of January 3, 2020 (the “Effective Date”) by and between Alvaxa Biosciences, Incorporated having a principal place of business at 2126 N. 51st Street, Seattle, WA 98103
(“Company”), and Fred Hutchinson Cancer Research Center (“Fred Hutch”), having a principal place of business at 1100 Fairview Avenue North, Seattle Washington 98109-1024, USA. 

INTRODUCTION 

WHEREAS, Company and Fred Hutch are parties to a confidentiality agreement entered into [***] (“CDA”); 

WHEREAS, certain Biological Materials (as defined below) were developed in the laboratory of [***] (“Principal
Investigator”) at Fred Hutch; 
 WHEREAS, Fred Hutch owns certain intellectual property rights in such innovations as listed
in this Agreement, which it desires to make available for development and commercialization; 
 WHEREAS, Company desires that Fred
Hutch grant it a non-exclusive license under such Biological Materials; 
 WHEREAS, Company
has represented to Fred Hutch, to induce Fred Hutch to enter into this Agreement, that Company has the desire, expertise and knowledge to develop, produce, market and sell the Developed Product and that it will commit itself to use commercially
reasonable efforts to develop and commercialize a program such that public benefit from the Developed Product will result; and 

WHEREAS, Fred Hutch, a nonprofit corporation exempt from federal income taxation under Section 501(c)(3) of the Internal Revenue
Code of 1986, as amended, organized and operated exclusively for charitable, scientific and educational purposes, has determined that this Agreement is in furtherance of its mission. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable
consideration, Fred Hutch and Company agree as follows: 
 1. DEFINITIONS 

In the terms defined and used herein, the singular will include the plural and vice versa. Undefined terms in this Agreement (other than names
of parties and Article headings) which are set forth in upper case letters have the meanings assigned to such terms in the succeeding Sections of this Article 1. 
  

	 	1.1	 	“510(k)” means a premarket submission to the FD&CA (as more fully defined in 21 CFR 807.92(a)(3) et seq) and not subject to PMA and all amendments and supplements thereto filed with the FD&CA,
or the equivalent application filed with any equivalent agency or governmental authority outside the United States of America (including any supra-national agency such as in the European Union), including all documents, data, and other information
concerning a device product which are necessary for gaining Regulatory Approval to market and sell such medical device. 

  
 Page 1 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	1.2	 	“Affiliate” means, with respect to any party, any person, corporation or other entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common
control with such party as the case may be, for as long as such control exists. As used in this Section 1.1, “control” shall mean: (a) to possess, directly or indirectly, the power to affirmatively direct the management and
policies of such person, corporation or other entity, whether through ownership of voting stock or by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of at least [***] (or such lesser
percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting stock or other ownership interest in such person, corporation or other entity. Company’s Affiliates as of the Effective Date
are set forth on Exhibit A to this Agreement. Notwithstanding the foregoing, Fred Hutch in not an Affiliate of Company. 

  

	 	1.3	 	“Antibody” or “Antibodies” shall mean any polyclonal or monoclonal antibodies that are produced or derived from, or contained within, the Biological Material including without
limitation, (i) fragments of the Antibody, (ii) genetically or biochemically modified versions of the Antibody, (iii) ribonucleotide, deoxyribonucleotide, or amino acids and/or sequences comprising thereof or which encode the sequence
of the variable regions (including VHHs) of the Antibody, (iv) chimeric or humanized versions of the Antibody, and (v) any derivative of any of the aforementioned. 

 

	 	1.4	 	“Biological Material” means [***]. For purposes of clarity, Biological Materials does not include [***]. 

  

	 	1.5	 	“Biologics License Application” or “BLA” means (i) a Biologics License Application as defined in the United States Federal Food, Drug and Cosmetic Act under the requirements of 21
CFR 600-680, or its successor regulation and applicable regulations promulgated thereunder from time to time, and all amendments and supplements thereto filed with the FDA or (ii) an equivalent
application, including, without limitation, a marketing authorization application, filed with any equivalent foreign agency or Governmental Authority (such as the EMEA in the European Union) requiring such filing, including all documents, data and
other information concerning a pharmaceutical product which are necessary for gaining Regulatory Approval to market and sell such pharmaceutical product. 

  

	 	1.6	 	“Confidential Information” of a party (the “transmitting party) means any non-public information or materials about or belonging to such a party hereto which
the other party is provided, has access to, or learns hereunder that relate to the transmitting party’s research or business and which are either identified as confidential at the time of disclosure or which the other party (the “receiving
party”) should reasonably know are deemed confidential by the transmitting party due to the nature of the information or the circumstances under which they were disclosed, including without limitation test data, samples, data, drawings, trade
secrets, draft and final correspondence with the United States Patent and Trademark Office and other patent authorities, but does not include materials or information that the receiving party can, prior to its proposed use or disclosure,
substantiate through written documentation: (a) is explicitly approved for public release by the transmitting party; (b) was already known by the receiving party with no obligation of confidentiality prior to receiving the information or
material from the transmitting party; (c) was lawfully disclosed to the receiving party by a third party having the right to disclose it without an obligation of confidentiality; (d) was publicly known or accessible at the time of
disclosure or later become part of publicly known or accessible through no fault or breach of obligation by the receiving party, its employees, or agents; or (e) was independently developed by the receiving party without use of the disclosing
party’s Confidential Information. Information about or included in the Biological Materials, that satisfies the foregoing definition shall be deemed Confidential Information belonging to Fred Hutch. Information about the terms, but not the
existence, of this Agreement shall be deemed Confidential Information belonging to both parties. 

  
 Page 2 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	1.7	 	“Developed Product” means a product or part of a product containing or derived from an Antibody in any form. For clarity, restrictions on Company’s right to possess, maintain or use Biological
Materials shall not in any way restrict Company’s right to develop, manufacture, or commercialize Developed Products (even if any such Developed Product contains any Biological Materials). 

 

	 	1.8	 	“Epitope Tags” mean solely the following: [***]. 

  

	 	1.9	 	“Field of Use” means any and all uses. 

  

	 	1.10	 	“First Commercial Sale” means the first transfer or disposition of a Developed Product for value to a party other than Company. Developed Product will be considered sold when delivered or invoiced,
whichever comes first. First Commercial Sale shall not include: (a) transfers or dispositions for bona fide charitable purposes or (b) when Developed Products are distributed alone, prior to receiving Regulatory Approval for sale or use of
such Developed Products, for pre-clinical, clinical, regulatory or governmental regulatory purposes. 

  

	 	1.11	 	“Governmental Authority” means any federal, state, national, supranational, local or other government, whether domestic or foreign, including any subdivision, department, agency, instrumentality,
authority (including any regulatory authority), commission, board or bureau thereof, or any court, tribunal or arbitrator. 

  

	 	1.12	 	“Indication” means a generally acknowledged disease or condition, a significant manifestation of a disease or condition, or symptoms associated with a disease or condition or a risk for a disease or
condition recognized by the FDA or equivalent regulatory authority for the purposes of labeling. 

  

	 	1.13	 	“IDE” means (i) an Investigational Device Exception application as defined and in 21 CFR 812 and all amendments and supplements thereto filed with the FDA or (ii) an equivalent application
filed with any equivalent foreign agency or governmental authority including all documents, data and other information concerning use of an investigational diagnostic product which are necessary for gaining Regulatory Approval to ship and use such
product in clinical investigations. 

  

	 	1.14	 	“IND” means (i) an Investigational New Drug application as defined and in 21 CFR 312.3 and all amendments and supplements thereto filed with the FDA or (ii) an equivalent application filed
with any equivalent foreign agency or Governmental Authority including all documents, data and other information concerning use of an investigational pharmaceutical product which are necessary for gaining Regulatory Approval to ship and use such
product in clinical investigations. 

  

	 	1.15	 	“Net Sales” means [***]. 

  

	 	1.16	 	“New Drug Application” means a New Drug Application (as more fully defined in 21 C.F.R. 314.5 et seq.) and all amendments and supplements thereto filed with the FDA, or the equivalent application filed
with any equivalent agency or governmental authority outside the United States of America (including any supra-national agency such as in the European Union), including all documents, data, and other information concerning a pharmaceutical product
which are necessary for gaining Regulatory Approval to market and sell such pharmaceutical product. 

  

	 	1.17	 	“Patient-selection Assay” means [***]. 

  
 Page 3 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	1.18	 	“Phase I Clinical Trial” means a human clinical trial that satisfies the requirements of 21 CFR 312.21(a), or its successor regulation or its equivalent in any other jurisdiction in the Territory.

  

	 	1.19	 	“Pre-Market Authorization” means authorization under a premarket approval application under Section 814(c) of the FD&CA requesting FDA’s approval to
commercially sell a medical device in the United States and its territories and possessions, including all information submitted with or incorporated by reference therein. 

 

	 	1.20	 	“Registrational Trial” means a human clinical trial that (a) satisfies the requirements of 21 C.F.R. §312.21(c), or its foreign equivalent (b) 21 C.F.R §812 and/or §814, or its
foreign equivalent or (c) is otherwise intended to provide sufficient efficacy data to support the filing of a marketing authorization approval, for which the applicable Regulatory Authority has agreed could serve as the basis for a Regulatory
Approval, which may include an accelerated Regulatory Approval. 

  

	 	1.21	 	“Regulatory Approval” means any approvals (including supplements, amendments, pre- and post-approvals and price approvals), licenses, registrations or
authorizations (including any designations of an indication for a Developed Product as an “Orphan Product” under the Orphan Drug Act), howsoever called, of any Regulatory Authority, which are necessary for the distribution,
importation, exportation, manufacture, production, use, storage, transport or clinical testing and/or sale of a Developed Product in a regulatory jurisdiction. Regulatory Approval will not include any site license for a Company manufacturing
facility. 

  

	 	1.22	 	“Regulatory Authority” means the United States Federal Drug Administration (“FDA”) or any counterpart of the FDA outside the United States, or other national, supra-national, regional,
state or local regulatory agency, department, bureau, commission, council, or other governmental entity or government sanctioned entity with authority over the distribution, importation, exportation, manufacture, production, use, storage, transport
or clinical testing and/or sale of a Developed Product hereunder. 

  

	 	1.23	 	“Regulatory Filings” means, collectively, New Drug Applications (NDAs), BLAs, NDAs, IDEs, INDs, establishment license applications (ELAs) and drug master files (DMFs), applications for designation of a
Product as an “Orphan Product(s)” under the Orphan Drug Act, Orange Book filings, responses to FDA “Written Requests,” or any other filings (including any foreign equivalents and further including any related
correspondence and discussions), and all data contained therein, as may be required by the FDA or equivalent Regulatory Authorities for the development, manufacture or commercialization of a Developed Product hereunder. 

 

	 	1.24	 	“Targets” mean [***]. 

  

	 	1.25	 	“Term” means the term of this license will begin on the Effective Date and will continue for twenty (20) years, unless otherwise terminated under Article 11 (Termination). 

 

	 	1.26	 	“Territory” means territory 

  

	 	1.27	 	“Third Party” means an individual or entity other than Fred Hutch and Company. 

  

	2.	 LICENSE GRANT 

 

	 	2.1	 	License Grant. Subject to the terms, conditions, and restrictions of this Agreement, Fred Hutch hereby grants to Company and its Affiliates during the Term, solely within the Territory and solely in the Field of
Use, a non-exclusive license to possess, maintain, and use the Biological Materials. For purposes of clarity, sublicensing of the Biological Materials is strictly prohibited under this Agreement.

  
 Page 4 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	2.2	 	Affiliates. Company may extend rights granted to Company under this Agreement to any of its Affiliates, provided that any such Affiliate must comply with and agree to comply with all terms and conditions of this
Agreement applicable to Company. Company hereby unconditionally guarantees the compliance with and performance by each of its Affiliates of all provisions of this Agreement. Company and its Affiliates who exercise rights under this Agreement will be
responsible and jointly and severally liable for all payments due pursuant to this Agreement. A breach of this Agreement by any of Company’s Affiliates will also be deemed a breach by Company. Company will provide Fred Hutch with an updated
list of all Affiliates from time to time upon Fred Hutch’s request within [***] of such request. 

  

	 	2.3	 	Limitation of Rights. No provision of this Agreement grants to Company, by implication, estoppel or otherwise, any rights other than the rights expressly granted it in this Agreement under the Biological
Materials, including any license rights under any other Fred Hutch-owned technology, copyright, know-how, patent applications, or patents, or any ownership rights in the Biological Materials.

  

	 	2.4	 	Reservation of Rights. Fred Hutch, on behalf of itself and its Affiliates and investigators, hereby reserves the right to utilize the Biological Materials for any purpose and/or to
non-exclusively license the Biological Materials to any Third Party with respect to both the Territory and Field of Use. All rights not specifically granted herein are reserved to Fred Hutch and no other
rights or license, whether express or implied, is granted in any of Fred Hutch’s or its Affiliates’ intellectual property rights. 

  

	 	2.5	 	Publication Rights. Fred Hutch reserves the right for itself and its affiliates and investigators to present, publish or otherwise disseminate the results of its and their research on the Biological Materials.

  

	 	2.6	 	The United States Government’s Rights. Biological Materials may have arose in whole or in part, from federally supported research and the federal government of the United States of America has certain rights
in and to such inventions as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal Regulation. The parties’ rights and obligations under
this Agreement to any government-funded inventions, including the grant of license set forth in Section 2.1 (License Grant), are subject to the applicable terms of the aforementioned United States laws. The U.S. Government is entitled, as a
right, under these Chapters: (a) to a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on the behalf of the U.S. Government any of the federally funded
inventions throughout the world and (b) to exercise march in rights on the federally funded inventions. Company agrees that, to the extent required by Title 35 Section 204 of the United States Code, it will substantially manufacture in the
United States of America all products embodying or produced through the use of a federally funded invention. 

  

	3.	 DUE DILIGENCE 

 

	 	3.1	 	Company will use commercially reasonable efforts and will cause any Affiliates to use commercially reasonable efforts, to develop and commercialize at least one Developed Product. 

 

	 	3.2	 	Reports. Company will also provide Fred Hutch annual reports (“Reports”) within [***] summarizing the development, marketing, manufacturing, sales, and Regulatory Approval progress made since the
previous year and will include sufficient detail to allow Fred Hutch to assess whether Company has met its obligations under Paragraph 3.1 to use commercially reasonable efforts. Company will provide Fred Hutch copies of any similar reports provided
by Company’s Affiliates. 

  
 Page 5 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	4.	 CONSIDERATION 

In consideration of the rights set forth herein, Company shall make the following payments to Fred Hutch: 

 

	 	4.1	 	Equity. Contemporaneously herewith and as partial consideration for the grant of the rights to Company set forth in this Agreement, Fred Hutch shall receive [***] (in the aggregate) of Company’s common
stock, with anti-dilution protection for up to $[***] of capital raised. Anti-dilution protection is not applicable in the event of, and shall no longer apply after, an acquisition as permitted under Section 10.1.Company hereby agrees to issue
to Fred Hutch common stock on terms to be mutually agreed to between the Parties within [***]. In the event of an acquisition as permitted under Section 10.1 in which Fred Hutch is to obtain equity securities in the acquirer, Fred Hutch shall
execute such agreements as are customary in connection with such transactions to be mutually agreed upon between the acquirer and Fred Hutch. 

  

	 	4.2	 	License Maintenance Fee. During the term and beginning on [***], Company will pay to Fred Hutch within [***] the license maintenance fee as follows: 

[***]. 
  

	 	4.3	 	Financial Milestones. Company will pay to Fred Hutch the following non-cumulative, non-creditable, and non-refundable milestone payments for the achievement of the milestone within [***] of achieving the corresponding milestone, whether achieved by Company, or its Affiliates as follows: 

4.3.1 For therapeutic use: 

[***] 
 For the above listed
milestone payments, payments will only become due once per Developed Product, regardless of repeated achievement of the same milestone with such Developed Product in multiple indications. For purposes of clarity, the above milestones will be due for
reach unique Target covered by a Developed Product. 
 4.3.2 For diagnostic use: 

[***] 
 For the above listed
milestone payments, payments will only become due once per Developed Product. For purposes of clarity, the above milestones will be due for reach unique Target covered by a Developed Product. 

 

	 	4.4	 	Consideration other than Monetary. Upon any sale, license or other distribution or disposal other than for monetary consideration, such Developed Product shall be deemed to be sold or used exclusively for money
at the average price during the applicable reporting period generally achieved in arms’ length transactions for such Developed Product in the country in which such sale, license or other distribution or disposal occurred when such Developed
Product is sole or use alone and not with other products (or, in the absence of such sales or licenses, at the fair market value of the Developed Product). 

  
 Page 6 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	4.5	 	Taxes and Other Fees. In addition to any other amounts due hereunder, Company shall pay, without any deduction to its Net Sales, all federal, state, municipal, foreign, and other governmental excise, sales, use,
property, customs, import, value added and other taxes, fees and levies of any nature that are assessed upon or with respect to the development, manufacture, use, offer, sale, license distribution, export or import of the Biological Materials or
otherwise arising in connection with this Agreement, other than United States taxes based on Fred Hutch’s income. If any withholding tax is imposed under the laws of a country or other taxing jurisdiction outside of the United States on any
amounts to be paid to Fred Hutch, such amounts will be increased by the amount of the withholding tax. Company shall be solely responsible for and shall pay any and all amounts required in the foreign location to be withheld, charged, deducted, or
assessed against such payment amounts and will promptly furnish Fred Hutch with certificates evidencing payment of such amounts. 

  

	 	4.6	 	Payments; Currency. All payments under this Agreement shall be made to “Fred Hutchinson Cancer Research Center” and remitted to the address in Section 9.1. All payments shall be made in U.S.
Dollars without set-off for currency conversion. With respect to Net Sales invoiced or expenses incurred in a currency other than U.S. Dollars, the Net Sales invoiced or expenses incurred shall be converted
into the US Dollar equivalent using a conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the applicable reporting/payment period. 

 

	 	4.7	 	Unpaid Amounts; Interest; Material Breach. Any sums which have not been timely paid by Company shall accrue interest from the original due date of each sum until the date of actual receipt of payment at the
annual rate of [***] or the maximum rate allowable by law, whichever is higher. Failure of Company to make timely payments under this Article 4 shall be deemed a material breach and eligible to Termination by Fred Hutch in accordance with Article
7.3. 

  

	 	4.8	 	Records; Audit. Company shall keep full, true and accurate books of accounts and other records containing all information necessary to ascertain and verify the remuneration payable to Fred Hutch hereunder for
each calendar year during the Term for a period of [***] after the end of each such applicable calendar year. At any time prior to the [***], Fred Hutch shall have the right to audit, or have an agent, accountant or other representative, audit such
books, records and all other material documentation of Company and its Affiliates relating to Net Sales and other payment obligations for such calendar year at reasonable times and upon reasonable notice. Fred Hutch shall only have the right to
conduct one audit per calendar year. Any period of time audited by Fred Hutch shall not be subject further audit. Should the audit lead to the discovery of a discrepancy to Fred Hutch’s detriment, Company shall pay the amount of the
discrepancy, plus interest, within [***] of written notice with the findings of the inspection. Fred Hutch shall pay the full cost of the inspection unless the discrepancy is greater than [***] to Fred Hutch’s detriment, in which case Company
shall pay the reasonable cost charged by such accountant for such inspection at the time of payment of the discrepancy. The books of accounts and other records of Company will be considered the Confidential Information of Company. 

 

	5.	 WARRANTY DISCLAIMER 

 

	 	5.1	 	Nothing in this Agreement will be construed as: 

  
 Page 7 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	a)	 	A warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents, copyrights, trade secrets or other
intellectual property of Third Parties; 

  

	 	b)	 	Granting by implication, estoppel or otherwise any licenses under proprietary rights of Fred Hutch other than Biological Materials; or 

 

	 	c)	 	An obligation to furnish any technology, technological information or other materials other than as expressly identified herein. 

  

	 	5.2	 	FRED HUTCH MAKES NO, HAS NOT MADE ANY, AND HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES OR LIABILITY WHATSOEVER WITH
RESPECT TO THE USE, SALE OR OTHER DISPOSITION BY COMPANY OR ITS AFFILIATES, VENDEES OR OTHER AGENTS OR TRANSFEREES OR END USERS OF DEVELOPED PRODUCTS INCORPORATING OR MADE BY USE OF ANY BIOLOGICAL MATERIALS UNDER THIS AGREEMENT, FURNISHED IN
CONNECTION WITH THIS AGREEMENT. THE FOREGOING ARE PROVIDED AS IS, WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, AND COMPANY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST
FRED HUTCH WITH RESPECT TO ANY OF THE FOREGOING. COMPANY SHALL BE SOLELY RESPONSIBLE FOR ALL REPRESENTATIONS AND WARRANTIES THAT COMPANY OR ITS AGENTS OR AFFILIATES MAKE TO THIRD PARTIES WITH RESPECT TO ANY OF THE FOREGOING. 

 

	6.	 PUBLICITY; MARKS; CONFIDENTIALITY 

 

	 	6.1	 	Publicity. Neither party will make any public press release or similar publicity announcement or disclosure regarding this Agreement without the other party’s prior written consent. The disclosing party will
provide copies of the proposed disclosure reasonably in advance (but in no event less than [***]) of such release or announcement for the non-disclosing party’s prior review and comment. The non-disclosing party will provide its comments, if any, on such announcement as soon as practicable. Notwithstanding the foregoing, either party will be permitted, without the need for consent, to make an objective
statement that this Agreement exists, without revealing its terms and conditions. 

  

	 	6.2	 	Use of Names, Logos or Symbols. No rights are granted in or to Fred Hutch’s or its Affiliates’ names, logos, trademarks or service marks (including, without limitation, the names “Fred
Hutchinson Cancer Research Center,” “FHCRC,” “Fred Hutch”), or the physical likeness or names of its employees or investigators or other symbols of Fred Hutch or its Affiliates for any purpose without its
prior written consent, other than as approved under Section 6.1 above. 

  

	 	6.3	 	 Confidentiality Obligations. Each party agrees to maintain such Confidential Information received from the
other party in strict confidence, to use it only in a manner consistent with the purpose for which it was transmitted and to not disclose it to Third Parties except to the receiving party’s employees, officers, directors, consultants,
contractors, subcontractors, counsel, and other agents who (a) have a need to know such information for purposes of assisting the receiving party in performing its obligations or exercising its rights hereunder, (b) have been advised of
the confidential nature of such information, and (c) are under binding obligations to maintain its confidentiality pursuant to terms which are at least as stringent as those set forth herein. Each party

  
 Page 8 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	 
agrees to take the same measures to protect the Confidential Information of the other party that it takes to protect its own information of comparable sensitivity, but in no event less than
reasonable care. All materials transmitted between the parties or accessed hereunder and containing Confidential Information will remain the property of the transmitting party and will, along with all copies, summaries and other tangible
manifestations thereof, be immediately returned upon termination or expiration of this Agreement or upon earlier reasonable request unless previously destroyed at the transmitting party’s request. Each party will, upon the other party’s
request, provide a written officer’s certificate certifying that it has so returned or destroyed the other party’s Confidential Information except that (i) one copy of such Confidential Information shall be maintained in the legal or
corporate development files for the sole purpose of ascertaining its ongoing rights and responsibilities in respect of such information, and (ii) the receiving party shall not be required to destroy any computer files stored securely by the
receiving party that are: (a) created during automatic system back up; or (b) retained for legal purposes by the legal division of the receiving party. Each party will be responsible for any breach of confidentiality hereunder by any of
its Affiliates, consultants, employees, independent contractors, and other agents. Each party will advise the other immediately in the event that it learns or has reason to suspect that unauthorized use, access, or disclosure of the other
party’s Confidential Information has or is likely to occur, and will reasonably cooperate with the other party to prevent or remedy the same. 

  

	 	6.4	 	Required Disclosures. Notwithstanding the foregoing, Fred Hutch and Company may disclose each other’s Confidential Information to the extent that it is required to be disclosed by law or regulation or is
reasonably required to be disclosed in order to enforce rights under the Agreement, provided that the receiving party will, if reasonably possible, notify the other party of the intended disclosure in advance, reasonably cooperate with the
disclosing party’s effort to seek a protective order contesting or limiting the disclosure and limit its disclosure to that which is required for the foregoing purpose. Fred Hutch may also disclose the terms and conditions of this Agreement to
the federal government and non-governmental funding entities and their respective agents as necessary in connection with any funding related to the Biological Materials. 

 

	 	6.5	 	Duration of Confidentiality Obligations. Notwithstanding the expiration or termination of this Agreement, the parties’ respective confidentiality obligations will continue in effect for [***] after the
expiration or termination of this Agreement. 

  

	 	6.6	 	Remedies. The parties each acknowledge and agree that a breach of this Article 6 may cause irreparable harm to the non-breaching party for which the award of money
damages may be inadequate. The parties therefore agree that in the event of any breach of this provision, the non-breaching party will be entitled to seek injunctive relief in addition to seeking any other
remedy provided in this Agreement or available at law. 

  

	7.	 EXPIRATION; TERMINATION 

 

	 	7.1	 	Expiration. This Agreement shall commence upon the Effective Date and expire, unless earlier terminated, upon expiration of the Term. [***] 

 

	 	7.2	 	For Convenience. Company may terminate this Agreement at any time by providing at least [***] written notice to Fred Hutch. 

  
 Page 9 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	7.3	 	For Breach. 

  

	 	a)	 	In the event that Company breaches any of its material obligations hereunder, Fred Hutch may at its sole option and discretion terminate this Agreement, provided that Fred Hutch will have first given Company written
notice specifying the nature of the breach and Company will have failed to cure such breach within [***]. If Company has begun to cure such breach and is diligently pursuing its cure if such breach is curable, but is not capable of being cured
within [***] of such notice, then Fred Hutch shall not exercise its termination rights for an additional [***] period as long as Company continues to diligently pursue its cure. 

 

	 	b)	 	In the event that Fred Hutch breaches any of its material obligations hereunder, Company may, upon written notice, terminate this Agreement, provided that it will have first given Fred Hutch written notice specifying
the nature of the breach and Fred Hutch will have failed to cure such breach within [***]. If Fred Hutch has begun to cure such breach and is diligently pursuing its cure if such breach is curable, but is not capable of being cured within [***] of
such notice, then Company shall agree to give Fred Hutch an additional [***] period to cure such breach as long as Fred Hutch continues to diligently pursue its cure. 

 

	 	7.4	 	For Company’s Bankruptcy or Insolvency. Fred Hutch may also terminate this Agreement by written notice to Company upon Company’s (i) becoming insolvent or otherwise unable to pay its debts as they
become due (unless Company cures such condition within [***] after receipt of written notice of a claim of insolvency by Fred Hutch); (ii) making a general assignment for the benefit of its creditors; or (iii) becoming the subject of a
voluntary or involuntary petition in bankruptcy or any voluntary or involuntary proceeding relating to receivership, liquidation, or composition for benefit of creditors under domestic or foreign bankruptcy or insolvency law. 

 

	 	7.5	 	General Effect of Termination; Survival. Upon expiration or termination of this Agreement, neither party shall be relieved of any obligations incurred prior to such expiration or termination, and the obligations
of the parties under any provisions which by their nature are intended to survive any such expiration or termination shall survive and continue to be enforceable, including, without limitation, those related to Articles 4 (Consideration), Article 6
(Publicity, Marks, Confidentiality), Article 7 (Expiration; Termination), Article 8 (Indemnification, Insurance, Limitation of Liability), and Article 10 (Miscellaneous). Termination or expiration of this Agreement for any reason shall not preclude
any party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. Upon termination (but not expiration) of this Agreement, Company and Affiliates will destroy any existing
Biological Materials in their possession, and provide written notification of said destruction to Fred Hutch within [***] of either the effective date of termination. Upon termination of this Agreement pursuant to either Section 7.2(a) or 7.3,
Company and Affiliates will cease all further development, manufacturing and commercialization of Developed Products. 

  

	 	7.6	 	Final Report to Fred Hutch. Within [***] following either the expiration or termination of this Agreement, Company will submit a final royalty report to Fred Hutch. Any payment obligations accrued prior to such
termination or expiration, including those incurred but not yet paid, will become due and payable at the same time as this final royalty report is due to Fred Hutch. 

 

	8.	 INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY 

 

	 	8.1	 	 Indemnification. Company will, at its sole expense, defend Fred Hutch and its Affiliates, and its and
their agents, directors, trustees, officers and employees (or anyone of them) against all third party claims, suits, actions, demands, or investigations (both governmental and non-governmental) (“Third
Party Claims”), and will indemnify, release and hold them harmless from and against any and all losses, damages, fees, liabilities, penalties or expenses (including, without limitation,

  
 Page 10 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	 
reasonable attorneys’ fees) incurred, assessed or awarded, under any theory of liability, including, without limitation, tort, warranty or strict liability, under any such Third Party Claim
to the extent arising out of or in connection with or alleged to arise out of or in connection with (i) the development, manufacture, use, commercialization, packaging, marketing or sale, lease, license or other distribution or disposition by
Company and its Affiliates or any of their agents of any Developed Product hereunder, (ii) the use by Company or its Affiliates or any of their agents or transferees of Biological Materials, or the use, marketing, promotion, sale or other
disposition by Company or its Affiliates or any of their agents or transferees Developed Products, or other products made by use of the Biological Materials; (iii) any representation or warranty made by Company or its Affiliates or agents to
Third Parties with respect to the Biological Materials or Developed Product; (iv) any claims for death, illness or personal injury caused by the Developed Products; or (v) any asserted violation by Company or its Affiliates or any of their
agents of any Export Laws or other applicable laws or regulations; or (vi) Company’s breach of any representation, warranty, covenant or obligation under this Agreement (each an “Indemnifiable Claim”), except to the extent
that an Indemnifiable Claim arises from or is caused by the gross negligence or willful misconduct of Fred Hutch, its Affiliates or its agents, directors, trustees, officers, or employees. Company also will reimburse Fred Hutch for its expenses,
including, without limitation, reasonable attorneys’ fees, in enforcing this provision. 

 To receive indemnification
from Company, Fred Hutch must: (i) notify the Company promptly of the assertion of any Indemnifiable Claim against it; provided that any delay by the Fred Hutch in giving notice to Company of an Indemnifiable Claim will not affect Fred
Hutch’s right to be indemnified for such Indemnifiable Claim except to the extent that Company is actually prejudiced in its ability to defend against such Indemnifiable Claim; and, (ii) authorize and permit Company to conduct and exercise
control of the defense and disposition of such claims, provided however, that Company agrees not to enter into any settlement or compromise of any claim or action in a manner that admits fault or imposes any restrictions or obligations upon an Fred
Hutch or otherwise adversely affects the rights of Fred Hutch without that Fred Hutch’s prior written consent, which will not be unreasonably withheld. 
  

	 	8.2	 	Insurance. Company will within [***] and continuing during the Term, carry workers’ compensation insurance in the amounts statutorily required, and occurrence-based liability insurance, including products
liability, general commercial liability and contractual liability, in an amount sufficient to cover the liability assumed by Company hereunder, such amount being [***]. Such policy will name Fred Hutch as an additional insured and require at least
[***] notice to Fred Hutch prior to any cancellation or material change. Company will provide Fred Hutch a certificate evidencing such coverages from time to time upon Fred Hutch’s reasonable request. The amounts of insurance coverage required
herein will not be construed as creating any limitation on Company’s indemnification obligations under this Agreement. 

  

	 	8.3	 	Exclusion of Damages; Limitation of Liability. NEITHER PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE TO ANY PARTY FOR SPECIAL, EXEMPLARY, INDIRECT, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER IN CONTRACT,
WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, THE BIOLOGICAL MATERIALS, AND DEVELOPED PRODUCTS, INCLUDING BUT NOT LIMITED TO DAMAGES MEASURING LOST PROFITS, GOODWILL OR BUSINESS OPPORTUNITIES,
EVEN IF ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 Page 11 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	8.4	 	Limitation of Liability. IN NO EVENT WILL FRED HUTCH’S AND ITS AFFILIATES’ TOTAL AND CUMULATIVE LIABILITY TOGETHER OF ANY KIND, EVEN FOR DIRECT DAMAGES, ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT, THE BIOLOGICAL MATERIALS, AND DEVELOPED PRODUCTS, EXCEED THE TOTAL AMOUNT OF THE PAYMENTS ACTUALLY RECEIVED BY FRED HUTCH. 

  

	9.	 NOTICES 

  

	 	9.1	 	Acceptable Forms of Notice. Unless otherwise provided in this Agreement, all communications, including, notices, demands or requests required or permitted to be given hereunder, will be given in writing and will
be: (a) personally delivered; (b) sent by telecopier or other electronic means of transmitting written documents; or (c) sent to the parties at their respective addresses indicated herein by registered or certified U.S. mail, return
receipt requested and postage prepaid, or nationally or internationally recognized courier service. The respective addresses to be used for all such, notices, demands, requests and other communications are as follows: 

If to Company: 

[***] 
 If to
Fred Hutch: 
 [***] 
  

	 	9.2	 	Effective Date of Notices. If personally delivered, such communication will be deemed delivered upon actual receipt. If electronically transmitted pursuant to this Section, such communication will be deemed
delivered when transmitted. If sent by overnight courier pursuant to this Section, such communication will be deemed delivered within [***] of deposit with such courier. If sent by U.S. mail pursuant to this Section, such communications will be
deemed delivered as of the date of delivery indicated on the receipt issued by the relevant postal service, or, if the addressee fails or refuses to accept delivery, as of the date of such failure or refusal. Any party to this Agreement may change
their address for the purpose of this Agreement by giving notice in accordance with this Article. 

  

	10.	 MISCELLANEOUS 

 

	 	10.1	 	Assignment. This is a personal contract between Fred Hutch and Company. Fred Hutch has selected Company because of the unique qualifications of its business, reputation, competitive posture, and the character of
its officers and principals. Neither this Agreement nor any of the rights or obligations hereunder may be assigned or otherwise transferred in whole or in part by Company, without the prior written consent of Fred Hutch; provided (a) either
party may assign this Agreement without such consent to any Affiliate, and (b) Company may assign this Agreement in connection with the sale of all or substantially all of Company’s assets to a Third Party in connection with a merger,
consolidation or reorganization of Company, provided, in each case that such party is in good standing under this Agreement at such time, and that the entity to which the Agreement is assigned agrees in writing to assume all of such party’s
obligations under this Agreement. Any attempt to so transfer without such written consent when it is required shall be void and of no effect. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties,
their legal representatives, heirs and assigns. 

  

	 	10.2	 	 Export Laws. It is understood that Fred Hutch is subject to United States laws and regulations controlling
the export of technical data, computer software, laboratory prototypes and other commodities, and that its obligations hereunder are contingent on compliance with all applicable United States export laws and regulations (“Export
Laws”). The transfer of certain technical data and/or commodities may require a license from the cognizant agency of the United States 

  
 Page 12 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	 
Government and/or written assurances by Company that Company and its Affiliates will not export data or commodities to certain foreign countries without prior approval of such agency. Fred Hutch
neither represents nor warrants that a license will not be required nor that, if required, it will be issued. In any event, Company specifically agrees not to export or re-export any information and/or
technical data and/or products in violation of any applicable laws and/or regulations. 

  

	 	10.3	 	Governing Law; Venue. This Agreement and all matters related thereto will be construed and interpreted under and governed by the laws of the State of Washington (without giving effect to principles and provisions
thereof relating to conflict or choice of laws irrespective of the fact that any one of the parties is now or may become a resident of a different state) and the federal patent, trademark, copyright and other applicable federal laws of the United
States of America, and not under the United Nations Convention on Contracts. Company and Fred Hutch hereby submit to the exclusive jurisdiction of the federal and state courts located in King County, Washington for the any dispute, claim or legal
proceeding arising out of or related to this Agreement, waive any objection to such jurisdiction on the grounds of venue, forum non conveniens, or similar ground, and agree that any such dispute, claim or proceeding will be brought exclusively in
one of those courts. 

  

	 	10.4	 	Force Majeure. Neither party will be liable for any default or delay in the performance of its obligations under this Agreement to the extent that such default or delay is caused, directly or indirectly, by acts
of God, civil disturbance, war, fires, acts or orders of any Government agency or official, other than Company’s failure to obtain Regulatory Approvals, natural catastrophes, or any other circumstances beyond such party’s reasonable
control. In any such event, the non-performing party will be excused from any further performance or observance of the obligation so affected only for as long as such circumstances prevail and such party
continues to use commercially reasonable efforts to recommence performance or observance as soon as practicable. Any party whose performance is delayed or prevented by any cause or condition within the purview of this Section will promptly notify
the other party thereof, the anticipated duration of the non-performance, and the action(s) being taken to overcome or mitigate the delay or failure to perform. Notwithstanding the foregoing, under no
circumstances will any delay or nonperformance be excused or forgiven (a) if the cause of the nonperformance could have been prevented or avoided by the exercise of reasonable diligence; (b) if the party whose performance is delayed or
prevented fails to use reasonable diligence to promptly overcome and mitigate the delay or failure to perform; or (c) if the nonperformance is caused by the negligence, intentional conduct or misconduct of the nonperforming party. The parties
understand and agree that governmental acts, orders or restrictions do not constitute excusing events hereunder if such acts, orders or restrictions are issued due to either party’s alleged failure to conform to applicable laws, regulations or
other governmental requirements. If the delay or non-performance lasts for more than [***], then the non-affected party may terminate this Agreement upon written notice
with respect to the countries in the Territory affected by the delay or non-performance. 

  

	 	10.5	 	 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as
to be effective and valid under applicable law. The provisions set forth in this Agreement will be considered to be severable and independent of each other. In the event that any provision of this Agreement will be determined to be unenforceable by
a court of competent jurisdiction with respect to any in any situation or jurisdiction, such determination will not be deemed to affect the enforceability of any other provision or the same provision in any other situation or jurisdiction and the
parties agree that any court making such a determination is hereby requested and empowered to limit or modify such provision and to substitute for such unenforceable provision a valid and enforceable provision that comes closest to expressing the
intention of the unenforceable provision, and the parties agree that such substitute provision will be as enforceable in said jurisdiction and 

  
 Page 13 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	 
situation as if set forth initially in this Agreement. Any such substitute provision will be applicable only in the country and situation in which the original provision was determined to be
unenforceable. However, in the event that such court declines to modify such provisions, then the parties will in good faith negotiate a modification to the provision to the minimum extent necessary to render it valid and enforceable in conformity
with the parties’ intent as manifested herein. 

  

	 	10.6	 	Construction. This Agreement will be construed and fairly interpreted in accordance with its terms, without any strict construction in favor of or against any party. Ambiguities will not be interpreted against
any party because of its role in preparing the Agreement. In construing or interpreting this Agreement, the word “or” will not be construed as exclusive, and the word “including” will not be limiting. The use of the
singular or plural form will include the other form and the use of the masculine, feminine or neuter gender will include the other genders. All captions and headings in this Agreement are for convenience only and will not be considered as
substantive parts of this Agreement or determinative in the interpretation of this Agreement. Unless otherwise stated, references in this Agreement to sections or exhibits refer to sections and exhibits of this Agreement. Except where specifically
stated to the contrary, whenever this Agreement requires any consent or approval to be given by either party, or either party must or may exercise discretion, the parties agree that such consent or approval will not be unreasonably withheld or
delayed, and that such discretion will be reasonably exercised. All exhibits and addendums to this Agreement will be deemed incorporated by reference and part of this Agreement. 

 

	 	10.7	 	Independent Contractors. The relationship between Fred Hutch and Company created by this Agreement is solely that of independent contractors. This Agreement does not create any agency, distributorship,
employee-employer, partnership, joint venture or similar business relationship between the parties. No party is a legal representative of another party, and no party has the right to assume or create any obligation, representation, warranty or
guarantee, express or implied, on behalf of another party for any purpose whatsoever. Each party will use its own discretion and will have complete and authoritative control over its employees and the details of performing its obligations under this
Agreement. 

  

	 	10.8	 	Entire Agreement; Amendment. This Agreement, together with its Exhibits, which are hereby incorporated by reference, contains the full understanding of the parties with respect to the subject matter hereof and
supersedes all prior understandings and writings relating thereto. However, the CDA shall not be superseded by this Agreement. The parties’ obligations under this Agreement shall be in addition to, and not in lieu of, the parties’
obligations under the CDA; to extent of any conflict or inconsistency between the CDA and the provisions of this Agreement relating to Confidential Information, this Agreement shall govern. This Agreement may not be modified or amended except by a
writing signed by both parties identified as an amendment to this Agreement. 

  

	 	10.9	 	Waiver. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the waiving party. Except as otherwise set forth in this Agreement, no
failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege
hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

  

	 	10.10	 	Counterparts. This Agreement may be executed in separate counterparts, each of which so executed and delivered will constitute an original, but all such counterparts will together constitute one and the same
instrument. Any such counterpart may comprise one or more duplicates or duplicate signature pages any of which may be executed by less than all of the parties provided that each party executes at least one such duplicate or duplicate signature page.
A facsimile, scanned, or photocopied signature (and any signature duplicated in another similar manner) identical to the original will be considered an original signature. 

  
 Page 14 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
properly and duly authorized officers or representatives as of the Effective Date. 
  

									
	Fred Hutch	  		  	Company
					
	By:	 	 /s/ Nicole C. Robinson, PhD
	  	    	  	By:	  	 /s/ Mai-Hope Le, MD

	Print Name: Nicole C. Robinson, PhD	  		  	Print Name: Mai-Hope Le, MD
	Title: VP & Deputy COO	  		  	Title: President & CEO
	Date: January 3, 2020	  		  	Date: January 6, 2020

  
 Page 15 of
16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 Exhibit A 

Company’s Affiliates 
 [***]

  
 Page 16 of
16 

 FIRST AMENDMENT TO NON-EXCLUSIVE LICENSE AGREEMENT

 THIS FIRST AMENDMENT TO NON-EXCLUSIVE LICENSE AGREEMENT (“First
Amendment”) is made and entered into as of March 30, 2020 (the “Amendment Date”), by and between Alvaxa Biosciences, Inc., having an address at 2126 N. 51’ Street, Seattle, WA 98103 (“Company”)
and Fred Hutchinson Cancer Research Center, having an address at 1100 Fairview Avenue North, Seattle, WA 98109 (“Fred Hutch”). Each of Company and Fred Hutch may be referred to herein as a “Party” or
collectively as the “Parties.” 
 WHEREAS, Company and Fred Hutch are parties to that certain Non-Exclusive License Agreement dated January 3, 2020 (the “License Agreement”), pursuant to which, among other things, Fred Hutch granted Company a
non-exclusive license to possess, maintain, and use certain biological materials; and 

WHEREAS, the Parties wish to amend the License Agreement to correct the territory of the licensed rights granted to Company under the
License Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises herein made and exchanged,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

1. Defined Terms. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings provided in the License
Agreement. 
 2. Amendment of Article 1 (Definitions). Effective as of the Effective Date of the License Agreement, Section 1.26
is hereby amended by replacing Section 1.26 with the following text. 
 “1.26 “Territory” means worldwide.”

 3. MISCELLANEOUS. 

(a) Effect of Amendment. The provisions of the License Agreement are hereby amended by the provisions of this First Amendment. Except as
expressly amended herein, the License Agreement shall remain in full force and effect in accordance with its terms. 
 (b)
Counterparts. This First Amendment may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This First Amendment may be executed by
electronic, facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. 
 Signature Page
to Follow 

  
 1 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this First Amendment to be
executed by their duly authorized representatives. 
  

									
	Alvaxa Biosciences, Inc.	  		  	Fred Hutchinson Cancer Research Center
					
	By:	  	 /s/ Mai Hope Le
	  	    	  	By:	  	 /s/ Patrick Shelby

	Name:	  	Mai Hope Le, MD	  		  	Name:	  	Patrick Shelby
	Title:	  	President and CEO	  		  	Title:	  	Director of Technology Management

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]